First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
9
10
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Perinatally HIV-infected infants can be infected with a drug-resistant virus or select for drug resistance by exposure to sub-therapeutic levels of maternal antiretroviral drugs present in breastmilk or from sub-therapeutic infant prophylaxis. We report a case of dolutegravir resistance detected in a treatment-naive perinatally HIV-infected infant whose mother was receiving tenofovir/lamivudine/dolutegravir. This case was detected during a national survey of HIV drug resistance in Haiti amongst infants testing positive for HIV through the national early infant diagnosis program between April 2020 and March 2021. This unique case underscores the need for prompt management of high viral loads in pregnant and breastfeeding women and supports HIV drug resistance surveillance efforts targeted at antiretroviral therapy-naive infants born to mothers in low-and middle-income countries.
Identifiants
pubmed: 37755428
doi: 10.1097/QAD.0000000000003653
pii: 00002030-202311010-00023
pmc: PMC10552825
doi:
Substances chimiques
Lamivudine
2T8Q726O95
Tenofovir
99YXE507IL
dolutegravir
DKO1W9H7M1
Anti-HIV Agents
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2097-2099Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach 2021. 2021. Available at: https://www.who.int/publications/i/item/9789240031593 . [Accessed 10 August 2021]
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial . Lancet 2021; 397:1276–1292.
Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, et al. DolPHIN-2 Study Group. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial . Lancet HIV 2020; 7:e332–e339.
Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis . EClinicalMedicine 2020; 28:100573.
Da Silva J, Vallabhaneni S, Pati R, Chun H, Malati C, Kiesa D, et al. Successful transition to tenofovir/lamivudine/dolutegravir (TLD) in PEPFAR-supported countries. International AIDS Society, Montreal Canada. 2022. Available at: https://programme.aids2022.org/Abstract/Abstract/?abstractid=10414 . [Accessed 11 October 2022]
Delaugerre C, Chaix M-L, Blanche S, Warszawski J, Cornet D, Dollfus C, et al. ANRS French Perinatal Cohort. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome . Retrovirology 2009; 6:85.
Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants . Pediatr Infect Dis J 2013; 32:e164–e169.
Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single- arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis . PLoS Med 2011; 8:1–10.
Inzaule SC, Jordan MR, Bello G, Wadonda-Kabondo N, Mounerou S, Mbulli IA, et al. Infant HIV Drug Resistance Survey Team. High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly diagnosed antiretroviral treatment-naive children in sub-Saharan Africa . AIDS 2020; 34:1567–1570.
Jordan MR, Penazzato M, Cournil A, Vubil A, Jani I, Hunt G, et al. Human immunodeficiency virus (HIV) drug resistance in African infants and young children newly diagnosed with HIV: a multicountry analysis . Clin Infect Dis 2017; cix698–cix1698.
World Health Organization(WHO); HIV drug resistance report 2021. 2021. Available at: https://www.who.int/publications/i/item/9789240038608 . [Accessed 03 January 2021]
Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study) . PLoS Med 2019; 16:e1002895.
Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding . AIDS 2016; 30:2731–2733.
World Health Organization. Surveillance of HIV drug resistance in children newly diagnosed with HIV by early infant diagnosis. 2017. https://apps.who.int/iris/bitstream/handle/10665/259732/9789241512541-eng.pdf?sequence=1&isAllowed=y . [Accessed 11 July 2023]
World Health Organization. WHO/HIVResNet HIV drug resistance laboratory operational framework-second edition. 2020. Available at: https://www.who.int/publications/i/item/978-92-4-000987-5 . [Accessed 16 June 2021]